Chronic Myeloid Leukemia: Arterial Occlusive Events in the PACE Trial

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.

A major molecular response at 3 months appears to increase the probability of overall survival in patients treated with ponatinib for chronic-phase chronic myeloid leukemia in the phase 2 PACE trial.

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.